Key result
Early diagnosis and targeted therapies limit progressive cardiovascular complications in Fabry disease.
Why the study?
Fabry disease causes cardiac involvement that limits quality of life and is the most common cause of death, with evolving understanding and treatment options requiring updated synthesis.
This review highlights the pathophysiology, imaging advances, and evolving treatment landscape, including enzyme replacement and oral chaperone therapies, for Fabry cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Supports early diagnosis to avert inflammation-driven fibrosis in Fabry cardiomyopathy; leaves open optimal sequencing of enzyme replacement and chaperone therapies.
Fabry disease (FD) is a rare X-linked inherited lysosomal storage disorder caused by deficient α-galactosidase A activity that leads to an accumulation of globotriasylceramide (Gb3) in affected tissues, including the heart. Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias, which limit quality of life and represent the most common causes of death. Following the introduction of enzyme replacement therapy, early diagnosis and treatment have become essential to slow disease progression and prevent major cardiac complications. Recent advances in the understanding of FD pathophysiology suggest that in addition to Gb3 accumulation, other mechanisms contribute to the development of Fabry cardiomyopathy. Progress in imaging techniques have improved diagnosis and staging of FD-related cardiac disease, suggesting a central role for myocardial inflammation and setting the stage for further research. In addition, with the recent approval of oral chaperone therapy and new treatment developments, the FD-specific treatment landscape is rapidly evolving.
No takes yet. Share an insight, caveat, or question.
Pieroni et al. (2021) conducted a review in Fabry disease. Fabry disease causes progressive cardiovascular complications, emphasizing the need for early diagnosis and evolving treatments like enzyme replacement and oral chaperone therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: